Ractopamine was approved by the US Food and Drug Administration for use as a growth promoter on cattle a decade ago is still banned by the European Union and most Asian countries. While, ractopamine residues in living samples and some organs (besides liver, muscle and kidney) of cattle under the recommended feed condition (10-30 mg/kg in dry matter, 28-42 days) remains unclear. In this study, nine cattle (246.22 ± 18.17 kg) were fed 0.67 mg/kg body weight (equivalent to 30 mg/kg in dry matter) of ractopamine for 28 days to investigate the residues of ractopamine in plasma, urine and organs. Plasma and urine were sampled during treatment and withdrawal period. Three cattle were slaughtered on withdrawal days 0 and 3 for organs collection. Ractopamine was determined by LC-MS/MS and its glucuronide metabolites were identified by Q-TOF/MS. Ractopamine concentrations in plasma and urine reached highest on treatment day 14 (2.88 ng/mL) and day 7 (4713.25 ng/mL), respectively. On withdrawal day 28, ractopamine concentrations in plasma and urine and were undetectable (limit of quantitation, 0.2 ng/mL) and 4.21 ng/mL, respectively. On withdrawal day 0, ractopamine residue in tissues were as follows: liver > eye > lung > spleen > aqueous fluid > heart > bile > kidney > gluteus > rib eye muscle. Compared with those on withdrawal day 0, ractopamine contents in most tissues that sampled on withdrawal day 3 were lower (P < 0.05), while that in the eye tissues, aqueous fluid, and kidney were stable or higher. These results provide extensive data for risk management in ractopamine approved countries and monitoring of the illegal usage in countries that ban ractopamine.
Introduction
The nutrient repartitioning effects of β-agonists in animals have been reported extensively. Although the use of one of the most well know β-agonists, clenbuterol, has been banned as a feed additive for food animals worldwide, a second β-agonist, ractopamine, had been approved by the US Food and Drug Administration (FDA) for use as a growth promoter in turkey, swine, and cattle (1) (2) (3) . However, all β-agonists, including ractopamine, are banned by the European Union and most Asian countries for use in feed and water for animals used for human consumption (4) . Considering that regulations governing ractopamine vary among countries, the residues of ractopamine in animals can be exploited for both risk assessment and monitoring of illegal usage. However, the residues of ractopamine in living samples, such as plasma and urine, and some organs, other than the liver, muscle and kidney, of cattle under FDA-recommended feed conditions (10-30 mg/kg in dry matter for 28-42 days) remains unclear. These data should be considered because besides the liver, muscle and kidney, other organs are also commonly used for human consumption in most Asian countries.
Previous studies have shown that cattle metabolize ractopamine into four major glucuronide metabolites (2) , which can be deconjugated by β-glucuronidase (5) . A conservative value of 12% for the amount of marker residue (parent ractopamine) of the total amount is used to set tolerances in liver and muscle tissues (2) . However, other studies revealed that the percentage of parent ractopamine of the total residues in urine was between 2.3-4.4% and 12.1-23.8% (6, 7) , and 49.6-97.3% in plasma (7) . Ractopamine residues in urine of cattle fed ractopamine for short periods have been reported (5) (6) (7) , although information regarding the FDA-recommended feeding conditions is somewhat limited. Elliott et al. (5) reported that ractopamine was no longer detectable in the urine of calves 2 weeks after withdrawal from administration of 0.1 mg/kg body weight of ractopamine for 17 days. Smith and Shelver (6) reported that parent and total ractopamine residues in urine were below the limit of quantitation (LOQ) (5 and 50 ppb before and after hydrolysis, respectively) on withdrawal days 4 and 6 of cattle fed 20 mg/kg of dietary ractopamine for 7 days. In our former study, the concentration of parent ractopamine residues in urine on withdrawal day 14 was 8.3 ng/mL and undetectable in plasma on withdrawal day 5 of cattle dosed with 2.01 mg/kg body weight ractopamine for 5 days (7). In regards to ractopamine residues in cattle tissues, data on muscle, liver, and kidney were reported by Elanco Animal Health (2). However, several other organs are also used for human consumption in most Asian countries. Thus, all these data should be considered for regulation in countries that either approve or ban the use of ractopamine.
Therefore, the objectives of the present study were to evaluate the residues of ractopamine in cattle under the FDA-recommended feed conditions. Beef cattle were administered 0.67 mg/kg body weight (equivalent to 30 mg/kg in dry matter) of ractopamine for 28 days. Then, ractopamine glucuronide metabolites were identified in plasma and urine by Q-TOF/MS and parent ractopamine residues were quantified in plasma, urine, and various tissues by LC-MS/MS.
Materials and methods

Chemicals and reagents
Ractopamine hydrochloride (93%) was provided by the Institute of Quality Standard and Testing Technology for Agro-Products, Chinese Academy of Agricultural Sciences (Beijing, China). A ractopamine hydrochloride standard (94.05%) was purchased from Sigma-Aldrich (Berlin, Germany) and ractopamine-d3 hydrochloride (98.5%) was purchased from C/D/N Isotopes, Inc. (Quebec, Canada). β-Glucuronidase was obtained from Merck KGaA (Darmstadt, Germany). Other chemicals and reagents used in this study were of chromatographic grade or higher.
Animal treatment and sampling procedure
Nine male Chinese Simmental beef cattle (body weight, 246.22 ± 18.17 kg) were fed 0.67 mg/kg body weight of ractopamine for 28 consecutive days. Ractopamine was mixed with 250 g of a mixture of crushed bran and corn and fed to the animals at 07:00 h before feeding of a normal mixed ration. The cattle had ad libitum access to feed and water, and were housed in separate pens to ensure accurate ractopamine ingestion. Other animal husbandry procedures were performed in accordance with the established procedures of the farm where the experiment was conducted.
Urine and blood samples were collected from three cattle during the entire experimental period. Urine was collected before treatment (blank) and on treatment days 1, 7, 14, 21, and 28 before every morning feeding, and withdrawal days 0, 3, 7, 14, and 28, filtrated, and stored at −20°C until assayed. Blood was collected at the same time points from the jugular vein into Vacutainer tubes (BD Biosciences, San Jose, CA, USA) containing heparin anticoagulant and centrifuged at 3,000 rpm for 10 min for the separation of plasma, which was then stored at −20°C until assayed. A captive bolt pistol was used for stunning and the animals were killed by bleeding. Three cattle were slaughtered on withdrawal days 0 and 3. Liver, kidney, lung, spleen, heart, bile, eye, gluteus medius (top sirloin) muscle and longissimus dorsi (rib eye) muscle were sampled and dissected into small pieces (about 5 g), and stored at −20°C until assayed. Control tissues were sampled from a 10th cattle fed the same mixed ration but without ractopamine.
All animal procedures were conducted in accordance with the Guidelines for Proper Conduct of Animal Experiments and according to the protocol approved by the Animal Care and Use Committee of the Chinese Academy of Agricultural Sciences. All efforts were made to minimize animal suffering.
Identification of ractopamine glucuronide metabolites by Q-TOF/MS
Pre-treatment To maximize detection of ractopamine metabolites, samples were extracted with acetonitrile only and received no other treatment. Briefly, samples (0.5 mL) were extracted twice with 2 mL of acetonitrile. Then, the extracts were dried under a stream of nitrogen gas at 50°C and the residues were dissolved in 0.5 mL of distilled water and filtered through a 0.2-μm filter (Waters Corporation, Milford, MA, USA) before assayed.
Separation and identification
High-performance liquid chromatography was used for separation of samples. Briefly, a 5-μL sample was injected into a ZORBAX Eclipse Plus C18 column (2.1 × 100 mm; particle size, 1.8 μm; Agilent Technologies, Santa Clara, CA, USA). The mobile phase consisted of 0.1% formic acid (solvent: water) and acetonitrile (5:95), and the pump flow rate was 0.2 mL/min. The identification of ractopamine metabolites was performed using an Agilent 6530 Q-TOF/MS system (Agilent Technologies, Santa Clara, CA, USA) in the Jet Stream electrospray ionization-positive (ESI+) mode. ESI conditions were as follows: dry gas temperature, 325°C (flow rate, 8 L/ min); sheath gas temperature, 350°C (flow rate, 12 L/min); capillary voltage (+), 3,500 V; nebulizer pressure, 35 psi; fragmentor, 175 V; and scan mass range (m/z), 100-1,100. After acquisition of the total ion chromatogram, an extracted ion chromatogram (EIC) was used to separate the peaks of the targeted metabolites and then a molecular formula was predicted. Last, the daughter ion spectrum of the targeted metabolites was obtained by ESI (+) at a collision energy of 20 V. All data were acquired and processed using MassHunter workstation software (Agilent Technologies, Santa Clara, CA, USA).
Determination of ractopamine by LC-MS/MS
Pre-treatment The urine and plasma preparation methods used in the present study were described in our previous report (7) . Briefly, 1-mL aliquots of the samples, 50 μL of ractopamine-d3 internal standard (100 ng/mL), 3 mL of ammonium acetate buffer (pH = 5.2), and 500 μL of 10% perchloric acid were added into a centrifuge tube, vortexed for 1 min, and then centrifuged at 8,000 rpm for 5 min. The supernatants were loaded onto an MCX cartridge (3 mL, 60 mg; Waters Corporation, Milford, MA, USA) that was activated with 3 mL of methanol and 3 mL of 0.1% formic acid. After washing with 3 mL of 0.1% formic acid and 3 mL of methanol, ractopamine was eluted with 3 mL of 5% ammonium methanol. The eluant was evaporated to dryness at 50°C under a stream of nitrogen gas. Residues were reconstituted in 1 mL of a 9:1 mixture of 0.1% formic acid and acetonitrile, filtered through a 0.2-μm filter (Waters Corporation Milford, MA, USA), and then concentrations were determined. Eyes were separated into eye tissues and aqueous fluid. Aqueous fluid and bile were pre-treated as described for urine and plasma. To determine the total residues of ractopamine in urine, 50 μL of β-glucuronidase was added and incubated at 37°C for 16 h, then perchloric acid was added and the other steps, as described above, were performed.
Tissue preparation methods were developed based on our previous work (8) . Briefly, tissues (5 g) were minced and homogenized in 20 mL of ammonium acetate buffer (pH = 5.2) and 50 μL of ractopamine-d3 internal standard mixture using a T18 Ultra Turrax Digital Homogenizer (IKA Works GmbH & Co. KG, Staufen, Germany) at 8,000 rpm for 1 min. The homogenates were centrifuged at 8,000 rpm for 5 min, then the supernatants were collected, mixed with 20 mL of hexane, and centrifuged at 12,000 rpm for 5 min. The upper hexane layer was discarded and the lower aqueous layer was filtered, then loaded onto a MCX cartridge (3 mL, 60 mg; Waters Corporation, Milford, MA, USA), and subjected to the same procedures described above for the urine and plasma samples.
LC-MS/MS analysis
The amount of ractopamine in all samples was determined using an ACQUITY Ultra-Performance LC chromatograph combined with a Xevo-TQ triple quadrupole mass spectrometer (Waters Corporation, Milford, MA, USA) in multiple reaction monitoring mode. A 5-μL sample was injected into an Acquity UPLC BEH C18 column (2.1 × 50 mm, 1.7 μm particle size; Waters Corporation, Milford, MA, USA) at 40°C. The mobile phase consisted of a gradient of 0.1% formic acid (A) and acetonitrile (B).
ESI-MS was achieved with one parent ion (m/z = 302.2) and two product ions (m/z = 107.14 and 164.17, respectively) for ractopamine, and one parent ion (m/z = 305.2) and two product ions (m/ z = 124.14 and 167.2, respectively) for ractopamine-d3. Nitrogen was used as the desolvation gas at a flow rate of 600 L/h. The capillary voltage was 3 kV and the cone voltage was 29 V. The ion source and desolvation temperatures were 150°C and 350°C, respectively.
Validation method
Stock ractopamine standard and internal standard stock solutions were diluted to form calibration standards and then spiked with different concentrations (0.5-40 ng/mL or g) to construct a standard curve. The accuracy and precision were evaluated by adding different concentrations of ractopamine to 1 mL (g) of blank urine, plasma or tissues. Then, the spiked samples were processed as described above. Ractopamine-d3 was added to all samples at a concentration of 5 ng/g for quantification. Six replications were used for intraday and interday measurements.
Statistical analysis
Results of ractopamine concentrations in samples are presented as the mean ± standard error (SE). Distribution normality and homogeneity of variances of the data were examined using Shapiro-Wilk and Levene test, respectively. The two tailed t-test was used to determine differences between the quantity of ractopamine residues on withdrawal days 0 and 3. A probability (P) value < 0.05 was considered statistically significant. The above analysis was performed using SPSS ver. 20.0 software (IBM-SPSS, Inc., Chicago, IL, USA).
Results
Validation of LC-MS/MS
The linearity of the LC-MS/MS method ranged from 0.5 to 40 ng/ mL, according to the calibration curve y = 997.89x (R 2 > 0.996).
The limit of detection (LOD, signal-to-noise = 3) of ractopamine was 0.05 ng/mL for plasma and urine, and 0.08 ng/g for tissues. The LOQ was 0.2 ng/mL for plasma and urine, and 0.3 ng/g for tissues (signalto-noise = 10). The accuracy and precision were evaluated by spiked different concentrations of ractopamine to blank urine, plasma, or tissues (Table I) . Coefficient of variation values changed from 1.3% to 11% (intraday) and 1.6% to 13% (interday). Intraday recoveries for plasma, urine and tissues were between 80.2% and 103.8%, while interday recoveries ranged from 81.8% to 100.3%.
Identification of ractopamine glucuronide metabolites
Six new peaks were observed in the EICs of treated cattle plasma and urine at an m/z ratio of 478.2065 ( Figure 1A , B). In accordance with the findings of a previous report (2) , the m/z ratios of ractopamine glucuronide metabolites A (ring A monoglucuronides, RS, SR), B (ring A monoglucuronides, RR, SS), and C (ring B monoglucuronides, mixture) were all the same (478.2065), thus the six new peaks included these three types. The daughter ion spectrum of the monoglucuronide metabolites at an m/z ratio of 478.2065 was also examined ( Figure 1C ) and most of the ion fragments were consistent with that of glucuronide combined with one of the phenolic hydroxyls. Typical fragment ions of ractopamine monoglucuronide, as reported previously (9) at m/z ratios of 460.196, 340.138, 284.164, 164.107, and 121.064 were all identified here. The parent and total ractopamine residues in urine are presented in Figure 2 . Total ractopamine residues in urine were highest on treatment day 7 at 10362.86 ng/mL and were still detectable on withdrawal day 28 at 8.9 ng/mL, and were dominated by ractopamine metabolites, which accounted for about 60% based on calculations at all time points.
Residues of ractopamine in plasma, urine, and tissues
The concentration of ractopamine residues in plasma reached highest on day 14 with 2.88 ng/mL and was 1.16 ng/mL on day 28 in the dosing period (Table II) . During the withdrawal period, ractopamine was no longer detectable in plasma on day 28 (LOQ ≤ 0.2 ng/mL). Compared with that in plasma, the ractopamine residues in urine were much higher and changed more rapidly, but with similar tendencies to that observed in plasma. During the dosing period, ractopamine residues in urine reached highest on day 7 at 4713.25 ng/mL and was 2063.48 ng/mL on day 28. Ractopamine content sharply eliminated in urine from 853.06 ng/mL on withdrawal day 0 to 4.21 ng/mL on day 28. There were significant differences in ractopamine residue concentrations in tissues on withdrawal days 0 and 3 (Table III) . On withdrawal day 0, the liver tissue had the highest concentration of ractopamine residues (119.41 ng/g), followed by eye tissues (109.97 ng/g), lung (58.77 ng/g), spleen (42.24 ng/g), aqueous fluid (18.2 ng/g), heart (12.02 ng/g), bile (10.5 ng/g), kidney (6.82 ng/g), and gluteus (4.3 ng/g) and rib eye (4.17 ng/g) muscles. The distribution of ractopamine in tissues on withdrawal day 3 slightly differed from that on day 0. The highest ractopamine residue concentration was in the eye tissues (124.35 ng/g). Also, with prolonged withdrawal time, ractopamine residues in most tissues (i.e., liver, lung, heart, and gluteus and rib eye muscles) were depleted (P < 0.05).
While in the eye tissues, aqueous fluid, and kidney tissues, the residue concentrations on withdrawal day 3 were higher than those on withdrawal day 0, and significant differences were observed in the kidney tissues (P < 0.05).
Discussion
Ractopamine metabolites
As described previously, cattle metabolize ractopamine to four major metabolites: A/B (ring A monoglucuronides), C (ring B monoglucuronide), and D (diglucuronide) (2). Lehner et al. (9) reported that ractopamine metabolism in equine species employs diverse mechanisms, including glucuronidation, sulfation, and methylation. Among these metabolic routes, glucuronidation was reported to be the major type of modification (10) . In this study, six new peaks were presented at an m/z ratio of 478.2065 in both plasma and urine of cattle treated with ractopamine. Daughter ion spectrum analysis showed that most of the typical ion fragments matched those in previous reports (9) , which were identified as ractopamine monoglucuronide metabolites. However, ractopamine diglucuronide metabolites were not identified in the present therefore, further studies are needed.
Residues of ractopamine in plasma, urine, and tissues
Plasma ractopamine concentrations can be used to evaluate the oral bioavailability of ractopamine in animals. Although ractopamine was approved by the FDA as a growth promoter in cattle more than 10 years ago, information regarding plasma residue concentrations remains limited. In our previous study, we found that the concentrations of parent ractopamine residues in plasma of dry dairy cows dosed with 2.01 mg/kg of ractopamine for 5 days continuously increased during the treatment period, but was undetectable on withdrawal day 5 (7). Here, we found that the concentration of parent ractopamine residues in plasma was less than the LOQ (0.2 ng/ mL) on withdrawal day 28, which may be explained by the lower metabolism rate of beef cattle, as compared to dairy cows. In comparison, investigations on plasma ractopamine concentrations in swine reported slightly greater levels (11, 12) . Qiang et al. (12) reported that total ractopamine in serum was undetectable (LOQ,1 ng/mL) on withdrawal day 2 of pigs fed 18 mg/kg of dietary ractopamine for 28 days. Also, Dalidowicz et al. (11) reported blood ractopamine concentrations of 40 and 10 ng/mL on withdrawal days 0 and 1, respectively, in pigs fed 30 mg/kg of dietary ractopamine for 4 days, which was less than the LOD (10 ng/mL) on withdrawal day 2. Together, results from these swine and cattle studies indicated that the plasma ractopamine concentration was very low during the dosing period and was rapidly undetectable during the withdrawal period.
Urine is regarded as one of the main routes of ractopamine expulsion by animals (13) . According to Elliott et al. (5), ractopamine residues in urine ranged from 44 to 473 ng/mL in cattle treated with 0.1 mg/kg body mass of ractopamine for 17 days during the dosage period and were no longer detectable 2 weeks after withdrawal. Meanwhile, in cattle fed 20 mg/kg of dietary ractopamine for 7 days, urinary concentrations of parent ractopamine residues were highest on day 5 (178.6 ng/mL) of the treatment period and less than the LOQ (5 ng/mL) on withdrawal day 4 (6). The elimination of ractopamine in urine of monogastric animals is similar to that of ruminants. Total ractopamine residues in urine in pigs fed 18 mg/kg of dietary ractopamine for 28 days reached the highest concentrations on treatment day 7 at 650.1 ng/mL and were undetectable (LOQ, 1 ng/mL) on withdrawal day 14 (12) . Together, these findings suggest that ractopamine residue concentrations in urine are relatively high during the treatment period and rapidly eliminate upon withdrawal. However, the elimination of ractopamine in urine was relatively slow in both our previous (7) and the present study, as compared to the rates reported by Elliott et al. (5) and Smith and Shelver (6) , which may be attributed to the greater amounts of administered ractopamine and the use of different animal species.
The tolerance level set by the FDA for parent ractopamine residues in cattle liver tissue is 0.09 mg/kg (12% of 0.75) and 0.03 mg/ kg (12% of 0.25) in muscle tissues (2) . The tolerance levels set by The Joint FAO/WHO Expert Committee on Food Additives are more strict (0.04 mg/kg in liver tissues, 0.09 mg/kg in kidney tissues, and 0.01 in muscle) (14) . In this study, the contents of ractopamine in gluteus, rib eye muscle and kidney on both withdrawal day 0 and day 3 were below the tolerance level, which indicated that ractopamine was rapidly eliminated in these tissues as reported before (2) . Ractopamine residues in spleen, heart, and bile also were depleted rapidly as withdrawal time prolonged. As the tolerances of ractopamine in these tissues were not included in the official list, the results presented in this study provide extensive data for further risk management.
On withdrawal day 0, the organs with the highest three residues concentrations (in descending order) were liver > eye tissue > lung. Comparatively, high ractopamine residue concentrations have been reported in liver tissues in both cattle and swine (2, 11, 12) , likely because the liver is the main metabolic organ for most drugs. It is Figure 2 . Parent and total ractopamine residues in urine of cattle (mean ± SE, n = 3) fed 0.67 mg/kg body weight of ractopamine for 28 days. T X and W X represent treatment and withdrawal day X. not surprising to find high ractopamine residue concentrations in lung tissues because ractopamine is a β-agonist in the same category as salbutamol, which is used for the treatment of human asthma. The three tissues with the greatest concentration of residual ractopamine in this study included the eyes, which was inconsistent with previously reported results (15, 16) . Smith et al. (16) demonstrated that the propensity for binding of ractopamine to melanin is weaker than that of clenbuterol and ractopamine was undetectable in whole-eye homogenates from cattle dosed with 0.9 mg/kg per day for 7 days. Likewise, Pleadin et al. (15) also reported low ractopamine residue concentrations in the ocular tissues of guinea pigs (0.34-1.20 ng/g) following administration of 3.5 mg/kg body mass of ractopamine for 7 days. However, in the present study, ractopamine residue levels were comparatively high in eye tissues. We deduced that this difference may have resulted from the longer treatment period in our study as compared to previous reports (28 vs. 7 days, respectively). Hence, the 28-day treatment regimen may have resulted in longer exposure and greater binding of ractopamine as compared with exposure for 7 days. The higher concentration of ractopaminein in eye tissues and aqueous fluid on withdrawal day 3 may be explained by the lower metabolism rate in eyes compared with other organs and the continuous transfer of ractopamine from the plasma to eyes at the beginning of the withdrawal period.
Conclusion
In summary, we identified glucuronide metabolites of ractopamine in plasma and urine of cattle fed ractopamine under the dosage and feeding period recommended by the FDA, and found that concentrations of parent ractopamine residues were relatively low in plasma, but high in urine, which were still detectable on withdrawal day 28. On withdrawal day 0, ractopamine residue concentrations in tissues were as follows: liver > eye tissues> lung > spleen > aqueous fluid > heart > bile > kidney > gluteus > rib eye muscle, of which the contents of ractopamine in muscles and kidney were below the tolerance level set by FDA and FAO/WHO. Besides, the amount of ractopamine depleted rapidly on withdrawal day 3 in most organs, while levels in eye tissues, aqueous fluids, and kidney tissues were higher than those on withdrawal day 0. These results provide extensive data for risk management in ractopamine approved countries and monitoring of the illegal usage in countries that ban ractopamine.
